Literature DB >> 35747565

Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease.

Derya Koyun1, Güldane Cengiz Seval1, Ekin Kırcalı1, Sinem Civriz Bozdağ1, Selami Koçak Toprak1, Pervin Topçuoğlu1, Muhit Özcan1, Önder Arslan1, Taner Demirer1, Osman İlhan1, Meral Beksaç1, Günhan Gürman1, Meltem Kurt Yüksel1.   

Abstract

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, the results of five SR-aGVHD patients received AAT evaluated. Complete response was seen 2 of four patients with gastrointestinal (GI) aGVHD, partial response in one GI and one liver aGVHD. The overall response rate was 80%. AAT is an effective and safe treatment option in SR-aGVHD. © Indian Society of Hematology and Blood Transfusion 2022.

Entities:  

Keywords:  AAT; SR-aGVHH

Year:  2022        PMID： 35747565      PMCID： PMC9209553          DOI： 10.1007/s12288-022-01524-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.915


  10 in total

1.  Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.

Authors:  James H Jerkins; Mehdi Hamadani; Felicia Zook; Narendranath Epperla; Bronwen E Shaw; Wael Saber; J Douglas Rizzo; Marcelo Pasquini; Saurabh Chhabra; William R Drobyski; Parameswaran N Hari; Nirav N Shah
Journal:  Am J Hematol       Date:  2017-07-29       Impact factor: 10.047

2.  Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Authors:  Isao Tawara; Yaping Sun; Eli C Lewis; Tomomi Toubai; Rebecca Evers; Evelyn Nieves; Tania Azam; Charles A Dinarello; Pavan Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

3.  α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

Authors:  John M Magenau; Steven C Goldstein; Dan Peltier; Robert J Soiffer; Thomas Braun; Attaphol Pawarode; Mary M Riwes; Maggi Kennel; Joseph H Antin; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Brian L Parkin; Gregory A Yanik; Sung Won Choi; Eli C Lewis; Charles A Dinarello; John Koreth; Pavan Reddy
Journal:  Blood       Date:  2018-02-02       Impact factor: 22.113

4.  Graft-versus-host disease treatment: predictors of survival.

Authors:  John E Levine; Brent Logan; Juan Wu; Amin M Alousi; Vincent Ho; Javier Bolaños-Meade; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-09       Impact factor: 5.742

5.  Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.

Authors:  Yi-Bin Chen; Miguel-Angel Perales; Shuli Li; Maria Kempner; Carol Reynolds; Jami Brown; Yvonne A Efebera; Steven M Devine; Areej El-Jawahri; Steven L McAfee; Thomas R Spitzer; Robert J Soiffer; Jerome Ritz; Corey Cutler
Journal:  Blood       Date:  2017-05-04       Impact factor: 22.113

6.  Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.

Authors:  Livia Giannoni; Florence Morin; Marie Robin; Marine Peyneau; Marie Hélène Schlageter; Deborah Desmier; Simona Pagliuca; Aurélien Sutra Del Galy; Flore Sicre de Fontbrune; Alienor Xhaard; Nathalie Dhedin; Hélène Moins-Teisserenc; Regis Peffault de Latour; Gerard Socié; David Michonneau
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-25       Impact factor: 5.742

7.  Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.

Authors:  Paula Rodriguez-Otero; Raphael Porcher; Régis Peffault de Latour; Margarita Contreras; Yoram Bouhnik; Aliénor Xhaard; Annalisa Andreoli; Patricia Ribaud; Nathalie Kapel; Anne Janin; Gérard Socié; Marie Robin
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

Review 8.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

9.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; John E Wagner; Todd E DeFor; Linda J Burns; Norma K C Ramsay; Stella M Davies; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

10.  Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.

Authors:  A Mario Marcondes; David Hockenbery; Marina Lesnikova; Charles A Dinarello; Ann Woolfrey; Terry Gernsheimer; Mahmoud Loghman-Adham; David Gelmont; Barry Storer; John A Hansen; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-17       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.